A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
NCT03006848
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients must be > 12 years of age but < 50 years of age at the time of enrollment.
- Patients must have histologic verification of osteosarcoma at initial diagnosis or relapse.
- Patients must have had evidence of having relapsed, progressed or become refractory to conventional therapy.
- Patients must have measurable disease, documented by clinical, radiographic or histologic criteria. Disease must be bi-dimensionally measurable by computed tomography (CT) or magnetic resonance imaging (MRI).
- Patients must have a performance status of ≥ 50 using the Karnofsky scale for patients > 16 years of age and the Lansky scale for patients ≤ 16 years of age.
- Patients must have a life expectancy of ≥ 6 weeks.
- Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
1. Myelosuppressive chemotherapy: must not have received within 3 weeks of entry onto this study.
2. Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent.
3. Immunotherapies: at least 42 days must have elapsed since a prior therapy that included a monoclonal antibody or any other type of immunotherapy (e.g. chimeric antigen receptor (CAR) T cell therapy).
4. Radiation therapy (RT): ≥ 2 weeks for local palliative RT (small port); ≥ 6 months must have elapsed if prior craniospinal RT or if ≥ 50% radiation of the pelvis; ≥ 6 weeks must have elapsed if other substantial bone marrow (BM) radiation.
- Organ Function Requirements:
1. Adequate bone marrow function defined as:
- Peripheral absolute neutrophil count (ANC) ≥ 1500/mm3
- Platelet count ≥ 100,000/mm3 (transfusion independent)
- Hemoglobin ≥ 9.0 g/dL (may receive RBC transfusions)
2. Adequate renal function defined as:
- Creatinine clearance or radioisotope GFR ≥70 mL/min/1.73m2 OR
- Serum creatinine based on age/gender as follows: (threshold creatinine values were derived from the Schwartz formula for estimating GFR).
- Age is: 12 to <13 years, then maximum creatinine is 1.2 mg/DL for male and female.
- Age is: 13 to <16 years, then maximum creatinine is 1.5 mg/DL for male and 1.4 mg/DL for female.
- Age is: ≥16 years, then maximum creatinine is 1.7 mg/DL for male and 1.4 mg/DL for female.
3. Adequate liver function defined as:
- Total Bilirubin ≤ 1.5x the institutional upper limit of normal (IULN) for age
- ALT (SGPT) and AST (SGOT) < 2.5 x IULN for age (or < 5 x IULN for patients with documented metastatic disease to the liver)
- Serum albumin > 2 g/dL
4. Serum lipase ≤ upper limit of normal (IULN).
5. Patients must have documented pulse oximetry ≥ 92% on room air.
- Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of enrollment.
- Male or female patients who are sexually active and of reproductive potential must agree to use an effective contraceptive method throughout the study and for at least 60 days after last avelumab treatment administration. Abstinence is an acceptable form of contraception.
- Patients must not currently be using other investigational agents.
- Patients must not currently be using other anti-cancer agent.
- Patients must be able to comply with the safety monitoring of the study in the opinion of the investigator.
- Written, informed consent and assent following Institutional Review Board, NCI, FDA and OHRP guidelines.
- Central nervous system (CNS) metastases.
- Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal,
inhaled, topical steroids, or local steroid injection (e.g., intra-articular
injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone
or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT
scan premedication).
- Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory
agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid
diseases not requiring immunosuppressive treatment are eligible.
- Active infection requiring systemic therapy.
- Known history of testing positive for HIV or known acquired immunodeficiency syndrome.
- Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive
HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
- Patient who has received vaccination within 4 weeks of the first dose of avelumab and
while on trials is prohibited except for administration of inactivated vaccines.
- Known prior severe hypersensitivity to investigational product or any component in its
formulations, including known severe hypersensitivity reactions to monoclonal
antibodies (NCI CTCAE v4.03 Grade ≥ 3).
- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular
accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months
prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart
Association Classification Class II, see Appendix II), or serious cardiac arrhythmia
requiring medication.
- Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however,
alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety
risk based on investigator's judgment are acceptable
- Other severe acute or chronic medical conditions including colitis, inflammatory bowel
disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent
(within the past year) or active suicidal ideation or behavior; or laboratory
abnormalities that may increase the risk associated with study participation or study
treatment administration or may interfere with the interpretation of study results
and, in the judgment of the investigator, would make the patient inappropriate for
entry into this study.
- Patients with active diarrhea > CTCAE v4.03 Grade 2.
- Patients who have previously received a prior organ transplantation, including
allogeneic stem cell transplantation.
- Female patients who are pregnant or actively breastfeeding.
- Patients who have previously received anti-PD1 or anti-PD-L1 therapy. Patients who
have previously received anti-CTLA-4 therapy (e.g. ipilimumab) are eligible for study.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Los Angeles, California
- New York, New York
- Memphis, Tennessee
- Houston, Texas
Descriptive Information | |||||
---|---|---|---|---|---|
Brief Title ICMJE | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | ||||
Official Title ICMJE | A Phase II Trial of Avelumab, A Fully Human Antibody That Targets Cells Expressing PD-L1, in Patients With Recurrent or Progressive Osteosarcoma | ||||
Brief Summary | This clinical trial seeks to determine if avelumab will be effective in facilitating removal of all gross tumor in the event of a relapse of osteosarcoma in pediatric patients. Avelumab will be evaluated using dosing that has previously been determined in adult studies. Primary Objectives:
Secondary Objective:
Exploratory Objectives:
| ||||
Detailed Description | This is a Phase 2 study using a traditional Simon two-stage design. Patients 12 years or greater with recurrent/refractory osteosarcoma will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles. Progression free survival and response to therapy after 4 cycles of treatment will be assessed. In addition, the toxicity profile of avelumab in this population will be closely monitored. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 2 | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||
Condition ICMJE | Osteosarcoma | ||||
Intervention ICMJE |
| ||||
Study Arms ICMJE | Experimental: Avelumab
All participants with recurrent/refractory osteosarcoma who consent to the study. Interventions: Avelumab and quality of life questionnaires. Interventions:
| ||||
Publications * | Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
Recruitment Information | |||||
Recruitment Status ICMJE | Active, not recruiting | ||||
Actual Enrollment ICMJE | 15 | ||||
Original Estimated Enrollment ICMJE | 40 | ||||
Estimated Study Completion Date ICMJE | January 31, 2023 | ||||
Actual Primary Completion Date | March 18, 2020 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||
Sex/Gender ICMJE |
| ||||
Ages ICMJE | 12 Years to 49 Years (Child, Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03006848 | ||||
Other Study ID Numbers ICMJE | OSTPDL1 NCI-2016-02036 ( Registry Identifier: NCI Clinical Trial Registration Program ) Pfizer W1211733 (OSTPDL1) ( Other Grant/Funding Number: Pfizer, Inc. ) Gateway RESAG ( Other Grant/Funding Number: Gateway for Cancer Research ) | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
| ||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Responsible Party | St. Jude Children's Research Hospital | ||||
Study Sponsor ICMJE | St. Jude Children's Research Hospital | ||||
Collaborators ICMJE |
| ||||
Investigators ICMJE |
| ||||
PRS Account | St. Jude Children's Research Hospital | ||||
Verification Date | March 2021 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |